deaths (OS)progression or deaths (PFS)RFS/DFS

metastatic, hormone-sensitive prostate cancer metastatic, hormone-sensitive prostate cancer

versus docetaxel plus ADT
darolutamide plus doxetaxel plus ADT vs. docetaxel plus ADT 1 certainty unassessablestatistically conclusive-29%--